NYSE$STVN

Stevanato Group S.p.A. · Q2 2026 earnings

Q2 2026 earnings · · Before market open · Investor relations

Briefing

Stevanato Group reported 8% revenue growth to €302.0 million for Q2 2026, with improved margins and updated full-year guidance.

Stevanato Group S.p.A. delivered solid Q2 2026 results with revenue up 8% year-over-year to €302.0 million, driven by 9% growth in the Biopharmaceutical and Diagnostic Solutions segment. High-value solutions reached 45% of revenue. Adjusted EBITDA margin expanded 280 basis points to 26.0%, while the company completed the divestiture of Balda C. Brewer and updated its 2026 guidance upward on organic growth and currency.

  • Revenue increased 8% to €302.0 million; high-value solutions revenue grew 16% to €135.9 million (45% of total).
  • Gross profit margin rose 60 bps to 28.7%; adjusted EBITDA margin improved 280 bps to 26.0%.
  • Adjusted diluted EPS rose to €0.14 from €0.11; reported diluted EPS €0.08 after €12.2M divestiture costs.
  • Updated FY2026 guidance: revenue €1.260B–€1.280B, adjusted EBITDA €335.0M–€345.2M, adjusted EPS €0.60–€0.62.

Headline financials

Total Revenue

€348M

Previous: €323M+7.6%
EPS (adj)

€0.14

Previous: €0.11+27.3%
Gross Margin

28.7%

No prior period
Net Debt

€360M

No prior period
Capital Expenditures

€52M

No prior period
High-Value Solutions Revenue

€136M

Previous: €117M+16.4%
Adjusted EBITDA Margin

26.0%

No prior period
Free Cash Flow

-€36.8M

No prior period
Net Income

€26.5M

Previous: €34.3M-22.8%
Operating Income

€44.9M

No prior period
Gross Profit

€99.8M

No prior period
Cash & Equivalents

€90.5M

No prior period

Revenue & EPS history

Stevanato Group · Revenue · Quarterly

€348M

Q2 2026+7.6%vs Q2 2025
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Stevanato Group · €302M total across 2 segments · Q2 2026

  • Biopharmaceutical and Diagnostic Solutions
    €266M
  • Engineering
    €35.8M

Forward guidance

Updated FY2026 guidance reflecting divestiture, better currency, and higher organic growth.

Tailwinds

  • Revenue range narrowed to €1.260B–€1.280B.
  • Adjusted EBITDA €335.0M–€345.2M.
  • Adjusted diluted EPS narrowed to €0.60–€0.62.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports

Historical avg

+1.4%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+3.0%

Avg return

30 days after

58%

11 / 19 earnings

Positive

+22.3%

Q2 2021

Best reaction

-18.9%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q4 2025+10.0%+1.9%-10.3%
Q3 2025-1.7%-3.3%-11.6%
Q2 2025-9.6%-7.6%-9.9%
Q1 2025+2.9%+12.0%+8.9%
Q4 2024+8.6%+8.8%+10.5%
Q3 2024+16.4%+12.4%+3.9%
Q2 2024+4.4%+8.5%+13.8%
Q1 2024-18.9%-20.7%-30.8%
Q4 2023-11.3%-14.1%-12.4%
Q3 2023-5.9%-2.5%-3.5%
Q2 2023+2.5%+5.6%+6.3%
Q1 2023-3.3%-1.5%+2.6%
Q4 2022+13.7%+5.2%+16.0%
Q3 2022+0.4%+9.1%+18.0%
Q2 2022+4.6%-3.4%-5.9%
Q1 2022+0.7%+8.7%+11.2%
Q4 2021-1.4%-4.2%+21.9%
Q3 2021-8.7%-11.2%-4.8%
Q2 2021+22.3%+27.0%+33.8%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro